Passage Bio Stock

passagebio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $225.5MM

Passage Bio is a genetic medicines company focused on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).

Register To Buy and Sell Shares

For more details on financing and valuation for Passage Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Passage Bio’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Passage Bio.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Jill Quigley JD
Chief Operating Officer, Operations
Gary Romano Ph.D
Chief Medical Officer
Tadataka Yamada MD
Co-Founder & Chairman
Richard Morris
Chief Financial Officer, Finance
James Wilson Ph.D
Co-Founder & Chief Scientific Advisor
Bruce Goldsmith Ph.D
Chief Executive Officer & Board Member
Alex Fotopoulos
Chief Technology Officer, Technology
Stephen Squinto Ph.D
Co-Founder, Board Member & Acting Head of R&D

Board Members

Bruce Goldsmith Ph.D
Sandip Kapadia
Thomas Woiwode Ph.D
Versant Venture Management
Liam Ratcliffe Ph.D
Stephen Squinto Ph.D
Patrick Heron
Frazier Healthcare Partners
Saqib Islam JD
Tadataka Yamada MD

Frequently Asked Questions About Passage Bio’s Stock

Can you buy Passage Bio’s stock?
Passage Bio is not publicly traded on NYSE or NASDAQ in the U.S. To buy Passage Bio’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Passage Bio’s stock?
Yes, you can sell stock of a private company like Passage Bio. Forge can help you sell your Passage Bio stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Passage Bio’s stock price?
Passage Bio is a privately held company and therefore does not have a public stock price. However, you may access Passage Bio’s private market stock price with Forge Data.
What is Passage Bio’s stock ticker symbol?
Passage Bio does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

InformedDNA Partners With Gene Therapy Firm Passage Bio on Dementia Genetic Testing
Xconomy: Passage Bio's IPO Raises $216M to Fund Gene Therapy Studies
Gene therapy developer Passage Bio priced its initial public offering at $18 per share, raising $216 million---72 percent more than it originally planned
Xconomy: Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again
Longtime biopharmaceutical executive Tachi Yamada helped keep the work of gene therapy pioneer James Wilson alive 20 years ago when Wilson was mired in
Updated on: Apr 19, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.